What is Encellin?
Founded in 2015 and headquartered in San Francisco, California, Encellin is at the forefront of developing regenerative materials through advanced cell transplant therapy. The company's proprietary soft cell encapsulation device (CED) is designed to protect transplanted cells within the body, enabling them to function as 'smart molecular factories.' This technology aims to address unmet needs in treating missing, damaged, or diseased cells, with initial therapeutic targets including chronic conditions such as hypoglycemia and hypocalcemia. Encellin's approach promises a novel way to deliver therapeutics precisely when needed.
How much funding has Encellin raised?
Encellin has raised a total of $15.8M across 2 funding rounds:
Angel/Seed
$5.9M
Other Financing Round
$9.9M
Angel/Seed (2021): $5.9M with participation from SV Latam Capital, Y Combinator, Khosla Ventures, and Sandhill Angels
Other Financing Round (2023): $9.9M led by Khosla Ventures and Y Combinator
Key Investors in Encellin
SV Latam Capital
SV LATAM Capital is an early-stage venture capital firm based in Silicon Valley with a focus on Latin American entrepreneurs. They invest in science and technology startups addressing significant global challenges, including healthcare innovations.
Y Combinator
Y Combinator is a renowned startup accelerator and seed funding provider established in 2005, known for supporting a wide range of early-stage technology businesses.
Khosla Ventures
Khosla Ventures is a venture capital firm that provides funding, strategic guidance, and operational support to technology companies, often focusing on disruptive innovations.
What's next for Encellin?
The recent major strategic investment in Encellin signals a critical growth phase for the company, likely enabling it to scale its operations, advance its clinical development pipeline, and further refine its cell encapsulation technology. With backing from prominent investors, Encellin is well-positioned to pursue its mission of transforming the treatment landscape for chronic diseases. The company's focus on regenerative materials and cell-based therapies places it in a rapidly expanding sector of the biotechnology market, suggesting a future trajectory aimed at significant clinical and commercial milestones.
See full Encellin company page
